65,437 trials
Renal Dialysis · Hemodiafiltration · Diastolic Dysfunction
Primary: Left Ventricular Diastolic Function Category — 15; 15; 5; 5 Participants — p=0.06
COVID-19
Primary: Part 1: Geometric Mean (GM) of Omicron BA.4/5 at Day 29 — 2340.9; 1753.8 AU/mL
Glaucoma
Primary: Total Acquisition Time (Both Eyes) — 4.44; 7.34; 7.71 minutes
Physiological Effects of Drugs · Anesthetics
Primary: Pain Perception Measured by the Wong-Baker FACES Pain Rating Scale — 1.04; 4.24 score on a scale
Pulmonary Fibrosis · Interstitial Lung Disease · Respiratory Disease
Primary: Change in Forced Vital Capacity (FVC) — 147.55; 167.72 mL
Smoking Cessation · Electronic Cigarette Use · E-Cig Use
Primary: Continuous Smoking Abstinence — 35; 20 Participants
Arginase 1 Deficiency
Primary: Change From Baseline in Plasma Arginine Concentrations in Subjects <24 Months of Age With Arginase 1 Deficiency (ARG1-D). — -221.53 μM
Advanced Solid Tumors · Non-small Cell Lung Cancer
Primary: Maximum Tolerated Dose — 250 mg
Chronic Kidney Diseases
Primary: Open Ended Free Text Question (Identifying Stakeholder Views on the 3 Most Important Outcomes for Self-management) — 75; 42; 19; 14 items
Mild to Moderate Hypertension
Primary: Number of Participants With Adverse Events (AEs) — 6; 6; 4; 0 Participants
BRAF V600E · Metastatic Colorectal Cancer
Primary: Safety Lead-in Phase (SLI): Incidence of Dose Limiting Toxicities (DLTs) — 0 Participants
Transplant Complication · CMV
Primary: Clinical Significant Leukopenia — 8; 1 Participants
Chronic Pain
Primary: Median Compliance Rate of Using Wearable Devices and Digital Surveys During the SCS Post-implant Period — 58.2; 36.0; 57.0; 44.9 percentage of days
Stress Urinary Incontinence
Primary: Number of Subjects With Urinary Retention — 15; 14 Participants
Liver Transplant · Hepatitis C
Primary: Adverse Events Due to Sofosbuvir/Velpatasvir (Epclusa) — 0; 0 Participants